Rubius Therapeutics has torn up its strategy. After reviewing human data on its lead candidates, the cell therapy biotech concluded investment in its two clinical prospects “is no longer justified,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback